When injected into the body, docetaxel doesn't discriminate between healthy and cancerous cells.
Not exact matches
Sengupta and his colleagues took breast cancer cells that
did not have the markings of CSCs and exposed them to
docetaxel, a common chemotherapy drug.
«Biomarkers determining who will or will not completely respond to neoadjuvant TCHP [trastuzumab, carboplatin,
docetaxel, and pertuzumab] are lacking,» wrote study authors led by Jeremy Force,
DO, of Duke University School of Medicine in Durham, North Carolina.
«In all the subgroups we tested the longer arm tended to be better than the shorter one, but we
did detect an interaction between
docetaxel dose and disease - free survival,» Joensuu said.
However, subset analyses of phase III trials suggest that patients with EGFR mutation - positive NSCLCs
do not benefit from immunotherapy compared with
docetaxel.